Skip to content
Companies

NeOnc Technologies

Intranasal perillyl alcohol for brain tumors

  • Westlake Village, CA
  • Founded 2023
  • Biotech
  • neonc.com

Raised to date

$27.3M

of $53M offered across 4 Form D filings

Still open
$25.7M
Investors
13
Last filed
Jun 25, 2026

About

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing pioneering treatments for central nervous system diseases, focusing primarily on brain cancers such as glioblastoma. The company's innovative approaches seek to overcome the formidable challenge of delivering therapeutics across the blood-brain barrier, which has historically hindered effective treatment options.

NeOnc's unique value lies in its proprietary nasal drug delivery system, which aims to enhance the effectiveness of treatments for brain cancers through a non-invasive administration method.

Funding

Mar 20252026
Now

$36M round, first sold Jan 2026: $10.6M sold, $25.4M still open

  • EquityFiled Jun 25, 2026Form D
    $5M/ $5M
  • EquityFiled Feb 9, 2026Form D
    $10.6M/ $36M
  • EquityFiled Apr 11, 2025Form D
    $1.6M/ $2M
  • EquityFiled Mar 24, 2025Form D
    $10M/ $10M

Product

NEO100

CNS Therapeutics

NEO100 is a highly purified form of perillyl alcohol (POH) that is administered intranasally. It is currently undergoing Phase II clinical trials specifically targeting patients with recurrent malignant glioma and malignant skull-based meningioma, aiming to provide an innovative solution in the treatment of these challenging CNS tumors.

  • Intranasal administration
  • Currently in Phase II clinical trials
  • Targets recurrent malignant glioma and skull-based meningioma

Built for

Patients with brain cancers

People on file